179524-45-9Relevant academic research and scientific papers
Aromatic heterocyclic derivatives as enzyme inhibitors
-
Page column 96, (2010/02/04)
The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.
Aromatic heterocyclic derivatives as enzyme inhibitors
-
, (2008/06/13)
The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.
AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS
-
, (2008/06/13)
The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.
Design and synthesis of a novel class of thrombin inhibitors incorporating heterocyclic dipeptide surrogates
Tamura, Susan Y.,Semple, J. Edward,Reiner, John E.,Goldman, Erick A.,Brunck, Terence K.,Lim-Wilby, Marguerita S.,Carpenter, Stephen H.,Rote, William E.,Oldeshulte, Gerard L.,Richard, Brigitte M.,Nutt, Ruth F.,Ripka, William C.
, p. 1543 - 1548 (2007/10/03)
Several potent and selective inhibitors of thrombin incorporating novel heterocyclic peptide surrogates in the P3-P2 position of peptidyl argininals have been discovered. Illustrated in this article are three classes of heterocycles: pyridones, uracils, and pyrimidinones. The synthesis and biological activities of these unique aromatic heterocyclic derivatives are reported herein.
AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS
-
, (2008/06/13)
The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.
